Supplementary Fig
These often feature: Stock video testimonials from patients Claims that injections are outdated Promises of painless, fast weight loss Fake headlines like FDA breakthrough now available over the counter These ads aim to capture impulse buyers with health concerns like obesity or diabetes
On May 15th, the journal Nature published a research paper titled "GLP-1-directed NMDA receptor antagonism for obesity treatment" by the Novo Nordisk team and the team led by Christoffer Clemmensen at the University of Copenhagen
Products claiming to prevent or treat disease, or to restore, correct or modify physiological functions, may be considered medicinal products requiring proper licensing
Lillys Oral GLP-1, Orforglipron, Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent with Injectable GLP-1 Medicines in Successful Phase 3 Trial
Why Fitness and Wellness Remain the Foundation No medication, supplement, or patch changes the underlying reality that the human body is built to move